As of 2024-12-15, the EV/EBITDA ratio of TG Therapeutics Inc (TGTX) is 876.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TGTX's latest enterprise value is 5,032.89 mil USD. TGTX's TTM EBITDA according to its financial statements is 5.74 mil USD. Dividing these 2 quantities gives us the above TGTX EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 15.5x - 19.0x | 16.6x |
| Forward P/E multiples | 16.7x - 27.3x | 21.0x |
| Fair Price | 0.26 - 10.32 | 4.08 |
| Upside | -99.2% - -67.8% | -87.3% |
| Date | EV/EBITDA |
| 2024-12-13 | 876.35 |
| 2024-12-12 | 840.30 |
| 2024-12-11 | 866.32 |
| 2024-12-10 | 866.86 |
| 2024-12-09 | 898.58 |
| 2024-12-06 | 928.12 |
| 2024-12-05 | 920.53 |
| 2024-12-04 | 926.77 |
| 2024-12-03 | 913.49 |
| 2024-12-02 | 959.57 |
| 2024-11-29 | 951.71 |
| 2024-11-27 | 957.13 |
| 2024-11-26 | 937.07 |
| 2024-11-25 | 946.56 |
| 2024-11-22 | 959.03 |
| 2024-11-21 | 944.93 |
| 2024-11-20 | 852.77 |
| 2024-11-19 | 830.27 |
| 2024-11-18 | 811.03 |
| 2024-11-15 | 809.13 |
| 2024-11-14 | 844.50 |
| 2024-11-13 | 954.42 |
| 2024-11-12 | 846.26 |
| 2024-11-11 | 841.66 |
| 2024-11-08 | 789.34 |
| 2024-11-07 | 764.68 |
| 2024-11-06 | 744.89 |
| 2024-11-05 | 709.38 |
| 2024-11-04 | 668.72 |
| 2024-11-01 | 737.57 |
| 2024-10-31 | 687.69 |
| 2024-10-30 | 689.59 |
| 2024-10-29 | 705.31 |
| 2024-10-28 | 668.45 |
| 2024-10-25 | 641.61 |
| 2024-10-24 | 637.82 |
| 2024-10-23 | 635.38 |
| 2024-10-22 | 665.74 |
| 2024-10-21 | 668.99 |
| 2024-10-18 | 640.26 |
| 2024-10-17 | 657.34 |
| 2024-10-16 | 672.51 |
| 2024-10-15 | 674.41 |
| 2024-10-14 | 627.25 |
| 2024-10-11 | 609.63 |
| 2024-10-10 | 600.14 |
| 2024-10-09 | 601.90 |
| 2024-10-08 | 600.41 |
| 2024-10-07 | 586.05 |
| 2024-10-04 | 610.98 |